Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Inclusion Criteria: * Age 18- 65 years * Body Mass Index (BMI) 18-30 * Chronic hepatitis C , diagnosed according to Chinese guideline of Hepatitis C (year 2004) * Detectable serum HCV-RNA by quantitative polymerase chain reaction assay and positive anti-HCV antibody * Female subjects of childbearing age with no history of menopause and negative pregnancy test, both female and male( including their partners ) subjects were required to conduct adequate contraception since screening until the 6 months after treatment * Volunteered to participate in this study, understood and signed an informed consent Exclusion Criteria: * Previous IFN treated patients * Hepatotoxic drugs was systematically used more than two weeks within past 6 months * Systemic therapy with potent immunomodulatory agents such as adrenocorticotropic hormone, thymosin α1, etc more than two weeks within past 6 months, not including corticosteroid nasal sprays, inhaled steroids and / or topical steroids * Co-infection with HAV, HBV, HEV, EBV, CMV and HIV * Evidences of hepatic decompensation, including but not limited to serum total bilirubin\> 2 times the upper limit of normal (ULN); serum albumin \<35g/L; prothrombin activity (PTA) \<60%; ascites, upper gastrointestinal bleeding and hepatic encephalopathy; Child-Pugh score B/C grade * Diagnosed with primary hepatocellular carcinoma or supported by evidences including but not limited to AFP\> l00ng/ml, suspicious liver nodules by imaging examinations * Liver diseases from causes other than HCV infection, including alcoholic liver disease, non-alcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis (antinuclear antibody titer higher than 1:100), hepatolenticular degeneration (Wilson's disease) and hemochromatosis, etc. * White blood cell count \<3×109/L; Neutrophil count\<1.5×109/L; platelet count\<90×109/L; hemoglobin below the lower limit of normal * Serum creatinine above the ULN * Serum creatine kinase\> 3 ULN * Diabetes mellitus or Poorly controlled Thyroid Diseases * Poorly controlled hypertension (systolic blood pressure\> 140mmHg, or diastolic blood pressure\> 90 mmHg) with hypertension -related retinal lesions * Immunodeficiency or autoimmune diseases including but not limited to inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, scleroderma, Sjogren's syndrome, autoimmune thrombocytopenia, etc. * Psychiatric and nervous system disorders, including history of Psychiatric illness or with family history (especially depression, depressive tendencies, epilepsy and hysteria, etc.) * Severe cardiovascular diseases (New York Heart Association functional class (NYHA) Ⅲ level and above, myocardial infarction occurred within past 6 months or PTCA performed within past 6 months, unstable angina, uncontrolled arrhythmias) * Serious blood disorders (all kinds of anemia, hemophilia, etc.) * Severe kidney disease (chronic kidney disease, renal insufficiency, etc.) * Serious digestive diseases (gastrointestinal ulcers, colitis, etc.) * Severe respiratory disease (pneumonia, chronic obstructive pulmonary disease, interstitial lung disease, etc.) * Retinal disease (retinal exfoliation, macular hole, retinal tumors, etc.) * Malignancies * Function organs transplant * Allergies or severe allergies, especially allergic to study drugs or any ingredients of the study drugs * Evidence of alcohol or drug abuse (average alcohol consumption male\> 40g / day, female\> 20g / day) * Pregnant or lactating women * Usage of prohibition drugs in this study * Participated in other clinical trials 3 months prior to the screening * Unwilling to sign the informed consent and adhere to treatment requirements * Other conditions not suitable for study judged by investigators